Source:http://linkedlifedata.com/resource/pubmed/id/16356831
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-12-16
|
pubmed:abstractText |
2-Methoxyestradiol (2-ME) is an endogenous metabolite of estradiol with promise for cancer chemotherapy, including advanced prostate cancer. We have focused on events related to cell cycle arrest (G1 and G2/M) and induction of apoptosis in human prostate cancer cells. Treatment with 2-ME increased cyclin B1 protein and its associated kinase activity followed by later inhibition of cyclin A-dependent kinase activity and induction of apoptosis. Similar results were obtained with paclitaxel (taxol), a clinically relevant agent used to treat advanced prostate cancer. Cyclin-dependent kinase inhibitors prevented 2-ME and paclitaxel-mediated increase in cyclin B1-dependent kinase activity and blocked induction of apoptosis. Reduction of X-linked inhibitor of apoptosis (XIAP) protein by 2-ME and paclitaxel correlated with increased apoptosis. Lower doses of 2-ME and paclitaxel resulted in G1 (but not G2/M) cell cycle arrest in the p53 wild type LNCaP cell line, but with minimal induction of apoptosis. We suggest that 2-ME and paclitaxel-mediated induction of apoptosis in prostate cancer cells requires activation of cyclin B1-dependent kinase that arrests cells in G2/M and subsequently leads to the induction of apoptotic cell death.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-methoxyestradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin B1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Tubulin Modulators
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0304-3835
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
8
|
pubmed:volume |
231
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
49-64
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:16356831-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:16356831-Apoptosis,
pubmed-meshheading:16356831-Cell Cycle,
pubmed-meshheading:16356831-Cyclin B1,
pubmed-meshheading:16356831-Cyclin-Dependent Kinases,
pubmed-meshheading:16356831-Estradiol,
pubmed-meshheading:16356831-Humans,
pubmed-meshheading:16356831-Male,
pubmed-meshheading:16356831-Paclitaxel,
pubmed-meshheading:16356831-Prostatic Neoplasms,
pubmed-meshheading:16356831-Tubulin Modulators,
pubmed-meshheading:16356831-Tumor Cells, Cultured
|
pubmed:year |
2006
|
pubmed:articleTitle |
2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells.
|
pubmed:affiliation |
Geriatric Research, Education, and Clinical Center and Research Service, Veterans Affairs Medical Center, GRECC (11-GRC), 1201 NW 16 Street, Miami, FL 33125, USA. cperez@med.miami.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.
|